Attached files
file | filename |
---|---|
8-K - FORM 8-K - CELGENE CORP /DE/ | c12823e8vk.htm |
EX-99.2 - EX-99.2 - CELGENE CORP /DE/ | c12823exv99w2.htm |
Exhibit 99.1
Contact:
Jacqualyn A. Fouse
|
Tim Smith | |
Sr. Vice President and
|
Director | |
Chief Financial Officer
|
Investor Relations | |
Celgene Corporation
|
Celgene Corporation | |
(908) 673-9956
|
(908) 673-9951 |
CELGENE ELECTS MICHAEL A. FRIEDMAN, MD TO BOARD OF
DIRECTORS
DIRECTORS
SUMMIT, NJ (February 16, 2011) Celgene Corporation (NASDAQ: CELG) today announced the
election of Michael A. Friedman, MD, to its Board of Directors. Dr. Friedman is an experienced
healthcare leader with a distinguished career in oncology research, regulatory strategy and public
healthcare policy. He currently serves as President and Chief Executive Officer of City of Hope, a
leading cancer research, treatment and education institution, as well as director of the
organizations Comprehensive Cancer Center and holder of the Irell & Manella Cancer Center
Directors Distinguished Chair. Before leading City of Hope, Dr. Friedman was senior vice president
of research and development, medical and public policy for Pharmacia Corporation and Chief Medical
Officer for biomedical preparedness at the Pharmaceutical Research and Manufacturers of America
(PhRMA). Additionally, Dr. Friedman previously served as deputy commissioner for the U.S. Food and
Drug Administration (FDA), later serving as acting commissioner, and as Associate Director of the
National Cancer Institute, National Institutes of Health.
Since 2004, Dr. Friedman has served on the Independent Citizens Oversight Committee, created by
California State Proposition 71 to govern the California Institute for Regenerative Medicine and
oversee implementation of Californias stem cell research effort.
In this time of increased focus on delivering therapeutic value within an evolving healthcare
system, someone as experienced in both medical research and public policy continues to strengthen
the capability of our Board of Directors, said Robert J. Hugin, Celgene Chief Executive Officer.
Dr. Friedmans guidance will be of tremendous value as we continue to deliver innovative therapies
to patients with cancer and other serious diseases around the world.
Dr. Friedman has received numerous commendations, including the Surgeon Generals Medallion in
1999. He holds a doctorate in medicine from the University of Texas and received his bachelors
degree from Tulane University. He completed postdoctoral training at Stanford University and the
National Cancer Institute and is certified in internal medicine and medical oncology.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical
company engaged primarily in the discovery, development and commercialization of novel therapies
for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more
information, please visit the companys Web site at www.celgene.com.
This release contains certain forward-looking statements which involve known and unknown risks,
delays, uncertainties and other factors not under the Companys control. The Companys actual
results, performance, or achievements could be materially different from those projected by these
forward-looking statements. The factors that could cause actual results, performance, or
achievements to differ from the forward-looking statements are discussed in the Companys filings
with the Securities and Exchange Commission, such as the Companys Form 10-K, 10-Q and 8-K reports.
Given these risks and uncertainties, you are cautioned not to place undue reliance on the
forward-looking statements.
# # #
2